Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11179MR)

This product GTTS-WQ11179MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF4 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_003327.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7293
UniProt ID P43489
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11179MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7061MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ3949MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ10447MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY-2495655
GTTS-WQ7558MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GC33
GTTS-WQ15423MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA TSR-033
GTTS-WQ6285MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CS-1001
GTTS-WQ14266MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RG-7116
GTTS-WQ12804MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMS721
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW